HC Wainwright & Co. Maintains Buy on BioAtla, Lowers Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Arthur He maintains a 'Buy' rating on BioAtla (NASDAQ:BCAB) but has lowered the price target from $17 to $10.
November 08, 2023 | 1:11 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
BioAtla's price target has been lowered from $17 to $10 by HC Wainwright & Co., though the 'Buy' rating is maintained.
The lowering of the price target by HC Wainwright & Co. could potentially lead to a negative sentiment among investors, which may put downward pressure on BioAtla's stock price in the short term. However, the maintained 'Buy' rating indicates that the analyst still sees potential in the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100